Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.48 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.47 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.45 |
| ▸ | MAP4K1 | Q92918 | 2/20 | 0.44 |
| ▸ | KARS1 | Q15046 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | HCRTR1 | O43613 | 5/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 5/20 | 0.43 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29614985 | 1.00 | USP30 (0.48) | USP30HRH4KDRHRH3MALT1 | |
| SCHEMBL20064100 | 0.91 | HRH3 (0.51) | USP30KDRHRH3MALT1KARS1 | |
| Hydrochloric Acid SCHEMBL3288531 | 0.90 | HRH3 (0.50) | USP30KDRHRH3MALT1KARS1 | |
| SCHEMBL20064025 | 0.88 | HRH3 (0.42) | USP30HRH4HRH3MALT1MAP4K1 | |
| SCHEMBL17843237 | 0.83 | USP30 (0.51) | USP30HRH3MALT1CHRM4HCRTR1 | |
| SCHEMBL30931655 | 0.81 | LRRK2 (0.50) | USP30HRH3MALT1HCRTR1HCRTR2 | |
| SCHEMBL15014494 | 0.79 | HRH3 (0.54) | USP30HRH3MALT1CHRM4HCRTR1 | |
| SCHEMBL30939096 | 0.79 | MALT1 (0.43) | USP30HRH3MALT1HCRTR1HCRTR2 | |
| SCHEMBL19011701 | 0.79 | HRH3 (0.56) | USP30HRH3MALT1CHRM4HCRTR1 | |
| SCHEMBL950877 | 0.78 | DPP4 (0.51) | KDRPRKCQDPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370784-B2 | Cyano-substituted heterocycles with activity as inhibitors of USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2022-06-28 | — | — | US | disclosed |
| US-20210284631-A1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2021-09-16 | — | — | US | disclosed |
| EP-3523291-B1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LTD (GB) | 2021-04-14 | — | — | EP | disclosed |
| WO-2018065768-A1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | MISSION THERAPEUTICS LIMITED (GB) | 2018-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284631-A1 | CYANO-SUBSTITUTED HETEROCYCLES WITH ACTIVITY AS INHIBITORS OF USP30 | USP30, USP28, USP1 | USP30 1/4885HRH4 4378/4885KDR 4475/4885 |
| US-11370784-B2 | Cyano-substituted heterocycles with activity as inhibitors of USP30 | USP30, USP28, USP1 | USP30 1/4885HRH4 4378/4885KDR 4475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.